Tumor Mutational Burden Results Explained: TMB-High and Immunotherapy

Updated

Tumor mutational burden, or TMB, estimates how many mutations are present in the tumor DNA assessed by a test. It is usually reported in mutations per megabase. It may inform an immunotherapy discussion, but it is neither a cancer diagnosis nor a guarantee of benefit.

How to read the number

Find the numerical score, units, assay name, specimen and the laboratory’s high or low classification. A score measures mutations within the DNA analyzed. It is not the number of cancers you have, your cancer stage or the percentage of your body affected.

A report may estimate TMB using a gene panel rather than sequencing the whole tumor genome. The method affects the estimate.

What TMB-high means

High is a test- and context-dependent classification. The FDA’s 2020 accelerated approval notice for pembrolizumab described TMB-high as at least 10 mutations per megabase using an FDA-approved test in a specified previously treated advanced solid-tumor setting.

That historical threshold is not a universal treatment instruction. Your team needs to check the current drug label, the assay, the tumor type, prior treatment and whether other satisfactory options exist.

Why high TMB does not guarantee a response

TMB is one piece of tumor biology. The relationship between the score and benefit varies across cancer types and clinical settings. A high score does not override every other finding or make immunotherapy appropriate for everyone.

Autoimmune disease, organ transplant history and previous immunotherapy experience may also affect treatment decisions. Those questions belong with the treating oncology team.

TMB is not MSI or PD-L1

TMB measures mutation burden, MSI evaluates microsatellite instability and PD-L1 assesses protein expression using a scoring system. They can overlap in some tumors, but none is a substitute for the others.

See MSI-high results and PD-L1 results. Ask how all relevant biomarkers fit together in your cancer.

Tissue TMB versus blood TMB

Blood and tissue measurements should not be assumed to be interchangeable. Tumor DNA levels, test design and analytical methods can affect the result.

If two scores disagree, first ask whether the specimens, time points and methods were comparable. A difference does not automatically mean the cancer became more aggressive or that treatment must change.

Questions to ask your oncology team

  • Which assay generated my score and how does it define high?
  • Was there enough tumor material for a reliable estimate?
  • Does TMB guide treatment in my cancer and current setting?
  • How do MSI, PD-L1 and driver alterations affect the interpretation?
  • Is an immunotherapy option approved for my circumstances or being considered in a trial?

Preparing for a personal review

Keep the complete report, not just a screenshot of the flagged line. Include previous results, scan reports and a brief treatment timeline if you decide to arrange a review. These details help distinguish what the test actually shows from questions it cannot answer.

MITOTICS® provides independent scientific interpretation and decision support. Kim Lockheimer, PhD, DFM, is a clinical scientist, not a physician. Diagnosis, prescribing and treatment decisions remain with your treating team. Do not change treatment based on this guide.

Frequently asked questions

What TMB score is considered high?

There is no universal cutoff for every assay and setting. The FDA’s 2020 notice used at least 10 mutations per megabase in a specified indication; current applicability needs checking.

Does TMB-high mean immunotherapy will work?

No. Response is not guaranteed, and treatment selection requires the full clinical context.

Are blood and tissue TMB interchangeable?

Not automatically. They may differ because of specimens, tumor DNA levels and assay methods.

References and further reading

  1. FDA 2020 pembrolizumab TMB-H approval notice
  2. Biomarker Testing for Cancer Treatment

A free 15-minute call is a brief conversation about your needs and whether personal review is appropriate. No records or payment needed.

Request a free 15-minute call